Fig. 1From: Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetesEpicardial and perirenal adipose tissue thickness (cm): placebo group (A–C) and dapagliflozin group (B–D). Data are mean ± SEM. * = p < 0.05Back to article page